{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=90", "query": { "condition": "Multi Center", "page": 90 }, "page_size": 10 }, "pagination": { "page": 90, "page_size": 10, "total_count": 6602, "total_pages": 661, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=91&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=89&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T00:02:45.349Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02579759", "title": "Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Charcot-Marie-Tooth Disease Type 1A" ], "interventions": [ { "name": "PXT3003 dose 1", "type": "DRUG" }, { "name": "PXT3003 dose 2", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharnext S.C.A.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "16 Years to 65 Years" }, "enrollment_count": 323, "start_date": "2015-12", "completion_date": "2018-08", "has_results": true, "last_update_posted_date": "2020-02-27", "last_synced_at": "2026-11-11T00:02:45.349Z", "location_count": 11, "location_summary": "Los Angeles, California • New Britain, Connecticut • Gainesville, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02579759" }, { "nct_id": "NCT01152346", "title": "Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Azacitidine for Injection", "type": "DRUG" }, { "name": "Vidaza®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bioniche Pharma USA LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2011-04", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2015-01-28", "last_synced_at": "2026-11-11T00:02:45.349Z", "location_count": 4, "location_summary": "Anaheim, California • Corona, California • Fresno, California + 1 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Corona", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01152346" }, { "nct_id": "NCT01802879", "title": "Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "Panobinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 9, "start_date": "2013-06-24", "completion_date": "2018-11-19", "has_results": true, "last_update_posted_date": "2019-12-06", "last_synced_at": "2026-11-11T00:02:45.349Z", "location_count": 4, "location_summary": "Duarte, California • Augusta, Georgia • Boston, Massachusetts + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01802879" }, { "nct_id": "NCT03063762", "title": "Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "RO6874281", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2017-03-20", "completion_date": "2021-06-14", "has_results": false, "last_update_posted_date": "2023-02-17", "last_synced_at": "2026-11-11T00:02:45.349Z", "location_count": 3, "location_summary": "New Haven, Connecticut • Chicago, Illinois • Baltimore, Maryland", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03063762" }, { "nct_id": "NCT01573624", "title": "Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "FF/GSK573719", "type": "DRUG" }, { "name": "FF", "type": "DRUG" }, { "name": "FF/VI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 421, "start_date": "2012-04-03", "completion_date": "2013-02-04", "has_results": true, "last_update_posted_date": "2017-10-06", "last_synced_at": "2026-11-11T00:02:45.349Z", "location_count": 4, "location_summary": "St Louis, Missouri • Medford, Oregon • Orangeburg, South Carolina + 1 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Medford", "state": "Oregon" }, { "city": "Orangeburg", "state": "South Carolina" }, { "city": "Spartanburg", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01573624" }, { "nct_id": "NCT00641303", "title": "Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anxiety Disorder", "Breast Cancer", "Depression", "Fatigue", "Hot Flashes", "Pain", "Sleep Disorders" ], "interventions": [ { "name": "acupuncture therapy", "type": "PROCEDURE" }, { "name": "sham intervention", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 51, "start_date": "2008-05", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2023-05-08", "last_synced_at": "2026-11-11T00:02:45.349Z", "location_count": 2, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00641303" }, { "nct_id": "NCT01818661", "title": "Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "PPA", "Non-fluent Aphasia", "Apraxia of Speech", "Primary Progressive Non-fluent Aphasia", "Primary Progressive Aphasia" ], "interventions": [ { "name": "AV-1451", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2018-07-01", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-11-11T00:02:45.349Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01818661" }, { "nct_id": "NCT01034176", "title": "BK Treatment Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "BK Viremia" ], "interventions": [ { "name": "levofloxacin", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2009-02", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2017-04-24", "last_synced_at": "2026-11-11T00:02:45.349Z", "location_count": 8, "location_summary": "Boston, Massachusetts • Burlington, Massachusetts • Worcester, Massachusetts + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Burlington", "state": "Massachusetts" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01034176" }, { "nct_id": "NCT03334617", "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Vistusertib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Cediranib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 528, "start_date": "2017-12-18", "completion_date": "2026-09-11", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-11-11T00:02:45.349Z", "location_count": 17, "location_summary": "Duarte, California • Fullerton, California • La Jolla, California + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03334617" }, { "nct_id": "NCT05277168", "title": "A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "SHR-A1904", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jiangsu HengRui Medicine Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2022-05-30", "completion_date": "2026-05", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-11-11T00:02:45.349Z", "location_count": 7, "location_summary": "Miami Beach, Florida • St. Petersburg, Florida • New Orleans, Louisiana + 4 more", "locations": [ { "city": "Miami Beach", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT05277168" } ] }